Fig. 1From: A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapyDuration on therapy and treatment-free intervals for patients in intermittent therapy phase (n = 5)Back to article page